DR REDDYS LABORATORIES LTD

Dr. Reddy's Laboratories Limited filed a Form 6-K with the U.S. Securities and Exchange Commission. The filing indicates the submission of an exhibit, specifically an "Intimation dated June 25, 2026." The content of this intimation is not detailed within the provided filing text.

Dr. Reddy's Laboratories Limited filed a Form 6-K with the SEC in June 2026. This regulatory filing primarily serves as an intimation regarding an upcoming Board Meeting, as detailed in Exhibit 99.1 of the submission.

Dr. Reddy's Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This launch expands the company's oncology portfolio and aims to improve patient access to affordable medicines. The product is a first-to-file and is eligible for 180-days of generic drug exclusivity for this strength in the U.S. Dr. Reddy's holds exclusive marketing rights, while MSN Laboratories developed and manufactured the product. The Bosulif® brand (400mg) had U.S. sales of approximately $253.8 million for the 12 months ended April 2026.

Dr. Reddy's Laboratories Limited filed a Form 6-K with the SEC on June 10, 2026. This filing indicates the submission of an 'Intimation dated June 10, 2026' as Exhibit 99.1. The specific details or nature of the intimation are not provided in the extracted text of this filing.

Dr. Reddy's Laboratories Ltd. announced the allotment of 12,100 fully paid-up equity shares, each with a par value of Re. 1/-, to eligible employees. This allotment was made on June 5, 2026, following the exercise of stock options under the Dr. Reddy's Employees Stock Options Scheme, 2002, and the Dr. Reddy's Employees ADR Stock Options Scheme, 2007. Following this issue, the total issued shares stand at 834,670,070, and the total issued share capital is Rs. 834,670,070/-.

Dr. Reddy's Laboratories Limited has filed a Form 6-K with the SEC on May, 2026. The filing includes an exhibit related to an intimation dated May 30, 2026. The report is submitted under the Securities Exchange Act of 1934.

Dr. Reddy's Laboratories Ltd. has filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, prepared by Makarand M. Joshi & Co., confirms that the company has complied with all applicable SEBI Regulations, circulars, and guidelines, including the Listing Regulations and Prohibition of Insider Trading Regulations. No deviations or non-compliances were observed during the review period, and all related party transactions received prior audit committee approval.

Dr. Reddy's Laboratories announced it has been invited to ring the Closing Bell at the New York Stock Exchange on May 29, 2026. This event celebrates the company's 25th anniversary of listing on the NYSE, a milestone achieved in April 2001 as the first pharmaceutical company from Asia, outside Japan, to do so. The ceremony will be attended by Dr. Reddy's senior management team, including Chairman Satish Reddy.

Dr. Reddy’s Laboratories Limited has filed a Form 6-K with the Securities and Exchange Commission on May 18, 2026. The filing includes an intimation dated May 18, 2026, as an exhibit.

Dr. Reddy's Laboratories announced that its management will participate in a series of analyst and institutional investor meetings from May 20 to June 3, 2026. These in-person group meetings are organized by various institutions including Elara Capital, Bank of America, Nomura, and Investec. The conferences will take place across multiple international locations including Hong Kong, Singapore, Toronto, Boston, New York, and Princeton, New Jersey.